Imaging Biomarkers of Glioblastoma Treatment Response: A Systematic Review and Meta-Analysis of Recent Machine Learning Studies.

artificial intelligence deep learning glioblastoma glioma machine learning meta-analysis monitoring biomarkers treatment response

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 21 10 2021
accepted: 03 01 2022
entrez: 17 2 2022
pubmed: 18 2 2022
medline: 18 2 2022
Statut: epublish

Résumé

Monitoring biomarkers using machine learning (ML) may determine glioblastoma treatment response. We systematically reviewed quality and performance accuracy of recently published studies. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis: Diagnostic Test Accuracy, we extracted articles from MEDLINE, EMBASE and Cochrane Register between 09/2018-01/2021. Included study participants were adults with glioblastoma having undergone standard treatment (maximal resection, radiotherapy with concomitant and adjuvant temozolomide), and follow-up imaging to determine treatment response status (specifically, distinguishing progression/recurrence from progression/recurrence mimics, the target condition). Using Quality Assessment of Diagnostic Accuracy Studies Two/Checklist for Artificial Intelligence in Medical Imaging, we assessed bias risk and applicability concerns. We determined test set performance accuracy (sensitivity, specificity, precision, F1-score, balanced accuracy). We used a bivariate random-effect model to determine pooled sensitivity, specificity, area-under the receiver operator characteristic curve (ROC-AUC). Pooled measures of balanced accuracy, positive/negative likelihood ratios (PLR/NLR) and diagnostic odds ratio (DOR) were calculated. PROSPERO registered (CRD42021261965). Eighteen studies were included (1335/384 patients for training/testing respectively). Small patient numbers, high bias risk, applicability concerns (particularly confounding in reference standard and patient selection) and low level of evidence, allow limited conclusions from studies. Ten studies (10/18, 56%) included in meta-analysis gave 0.769 (0.649-0.858) sensitivity [pooled (95% CI)]; 0.648 (0.749-0.532) specificity; 0.706 (0.623-0.779) balanced accuracy; 2.220 (1.560-3.140) PLR; 0.366 (0.213-0.572) NLR; 6.670 (2.800-13.500) DOR; 0.765 ROC-AUC. ML models using MRI features to distinguish between progression and mimics appear to demonstrate good diagnostic performance. However, study quality and design require improvement.

Identifiants

pubmed: 35174084
doi: 10.3389/fonc.2022.799662
pmc: PMC8842649
doi:

Types de publication

Systematic Review

Langues

eng

Pagination

799662

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022 Booth, Grzeda, Chelliah, Roman, Al Busaidi, Dragos, Shuaib, Luis, Mirchandani, Alparslan, Mansoor, Lavrador, Vergani, Ashkan, Modat and Ourselin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Sci Rep. 2018 Aug 21;8(1):12516
pubmed: 30131513
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Sci Rep. 2020 Nov 23;10(1):20331
pubmed: 33230285
J Neurooncol. 2019 Jan;141(2):347-354
pubmed: 30414096
IEEE Trans Pattern Anal Mach Intell. 2021 Nov;43(11):4037-4058
pubmed: 32386141
J Med Biol Eng. 2021;41(2):115-125
pubmed: 33293909
Radiol Artif Intell. 2020 May 27;2(3):e190043
pubmed: 32510054
JCO Clin Cancer Inform. 2019 Jan;3:1-12
pubmed: 30673344
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Radiology. 2013 Mar;266(3):842-52
pubmed: 23204544
Clin Radiol. 2016 May;71(5):495-6
pubmed: 26896081
Neuro Oncol. 2020 Oct 14;22(10):1516-1526
pubmed: 32319527
J Neural Eng. 2020 Apr 30;17(2):021002
pubmed: 32191935
J Clin Oncol. 2006 Mar 10;24(8):1228-35
pubmed: 16525177
Neuro Oncol. 2017 Jan;19(1):89-98
pubmed: 27580889
Clin Radiol. 2020 Jan;75(1):20-32
pubmed: 31371027
Neuroradiology. 2019 Nov;61(11):1261-1272
pubmed: 31289886
Neuro Oncol. 2019 Feb 19;21(3):404-414
pubmed: 30107606
Neuro Oncol. 2020 Apr 15;22(4):450-456
pubmed: 31844891
J Neurooncol. 2020 May;147(3):681-690
pubmed: 32239431
Eur J Radiol. 2011 May;78(2):259-65
pubmed: 21444166
Eur Radiol. 2021 May;31(5):2933-2943
pubmed: 33151394
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
Lancet Neurol. 2010 Sep;9(9):906-20
pubmed: 20705518
Br J Cancer. 2020 Feb;122(3):295-305
pubmed: 31666668
AJNR Am J Neuroradiol. 2020 Aug;41(8):E52-E59
pubmed: 32732276
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
J Clin Epidemiol. 1996 Nov;49(11):1225-31
pubmed: 8892489
Nat Commun. 2019 Jul 18;10(1):3170
pubmed: 31320621
Neuro Oncol. 2017 Jan;19(1):118-127
pubmed: 27502247
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
J Neurooncol. 2007 Mar;82(1):81-3
pubmed: 16944309
J Clin Epidemiol. 2005 Oct;58(10):982-90
pubmed: 16168343
Comput Math Methods Med. 2018 Jun 13;2018:8572058
pubmed: 30008798
Med Phys. 2020 Mar;47(3):1139-1150
pubmed: 31885094
PLoS One. 2017 May 17;12(5):e0176528
pubmed: 28520730
Cancers (Basel). 2020 Oct 22;12(11):
pubmed: 33105661
Cancer. 2020 Jun 1;126(11):2625-2636
pubmed: 32129893
Radiol Artif Intell. 2020 Mar 25;2(2):e200029
pubmed: 33937821
Br J Cancer. 2019 Jan;120(1):54-56
pubmed: 30478409
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):603-613
pubmed: 30276440
NMR Biomed. 2019 Feb;32(2):e4042
pubmed: 30556932
Stat Med. 2008 Feb 28;27(5):687-97
pubmed: 17611957
Neuro Oncol. 2020 Jun 9;22(6):886-888
pubmed: 32152622
AJNR Am J Neuroradiol. 2018 Dec;39(12):2187-2193
pubmed: 30385468
JAMA. 2017 Aug 8;318(6):517-518
pubmed: 28727867
Cancer Manag Res. 2020 May 07;12:3191-3201
pubmed: 32440216
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Radiother Oncol. 2019 Feb;131:66-74
pubmed: 30773189
Neuro Oncol. 2015 Jan;17(1):151-9
pubmed: 25038253
Eur Radiol. 2021 May;31(5):3127-3137
pubmed: 33128598
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Front Oncol. 2021 Feb 09;11:620070
pubmed: 33634034
J Neurooncol. 2015 Jan;121(2):423-4
pubmed: 25366364
Neurooncol Adv. 2019 Sep 01;1(1):vdz019
pubmed: 32642655
J Clin Neurosci. 2019 Dec;70:11-13
pubmed: 31648967
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neuro Oncol. 2013 May;15(5):515-34
pubmed: 23325863
Health Care Manage Rev. 2011 Oct-Dec;36(4):338-48
pubmed: 21685794
J Med Imaging (Bellingham). 2018 Jan;5(1):011018
pubmed: 29340286
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967367

Auteurs

Thomas C Booth (TC)

School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.
Department of Neuroradiology, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Mariusz Grzeda (M)

School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.

Alysha Chelliah (A)

School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.

Andrei Roman (A)

Department of Radiology, Guy's & St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
Department of Radiology, The Oncology Institute "Prof. Dr. Ion Chiricuţă" Cluj-Napoca, Cluj-Napoca, Romania.

Ayisha Al Busaidi (A)

Department of Neuroradiology, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Carmen Dragos (C)

Department of Radiology, Buckinghamshire Healthcare National Health Service Trust, Amersham, United Kingdom.

Haris Shuaib (H)

Department of Medical Physics, Guy's & St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

Aysha Luis (A)

Department of Neuroradiology, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Ayesha Mirchandani (A)

Department of Radiology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom.

Burcu Alparslan (B)

Department of Neuroradiology, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.
Department of Radiology, Kocaeli University, İzmit, Turkey.

Nina Mansoor (N)

Department of Neuroradiology, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Jose Lavrador (J)

Department of Neurosurgery, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Francesco Vergani (F)

Department of Neurosurgery, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Keyoumars Ashkan (K)

Department of Neurosurgery, King's College Hospital National Health Service Foundation Trust, London, United Kingdom.

Marc Modat (M)

School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.

Sebastien Ourselin (S)

School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London, United Kingdom.

Classifications MeSH